Diabetes Complications

Data demonstrate major risk stratification benefits of Lp-PLA2 in diabetic patients

Published in Obesity and Diabetes Week, December 12th, 2005

diaDexus announced findings from two studies demonstrating that high levels of the proinflammatory enzyme, lipoprotein-associated phospholipase A2 (Lp-PLA2), are associated with an increased risk in cardiovascular disease across multiple populations.

All results were presented at the American Heart Association scientific sessions. The first study, "Lipoprotein-Associated Phospholipase A2 may Differentially Predict the Presence of Angiographic Coronary Artery Disease and Coronary Death across Glycemic Categories," showed that in diabetic patients, Lp-PLA2 conferred a greater than 2-fold increase in risk of coronary artery disease (CAD) or death from CAD, independent of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week

Source: Obesity and Diabetes Week (2005-12-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry